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problems
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Our understanding of renal magnesium handling has been
greatly expanded by research performed over this decade. Control
of total body magnesium homeostasis principally resides within
the nephron segments of the kidney. Magnesium is handled in
different ways along the nephron segments (Fig. 1). About 80% of
the total plasma magnesium (0.65 to 1.2 mM) is filtered through
the glomerular membrane. Of the ultrafilterable magnesium (0.5
to 0.9 mM), 5 to 15% is reabsorbed by the proximal tubule,
including the convoluted and straight portions. This is distinct
from sodium and calcium where — 70 and —60%, respectively, are
reabsorbed in the proximal nephron segments. Accordingly, the
delivery of magnesium to the thick ascending limb of the loop of
Henle is relatively much larger than that of sodium and calcium.
Proportionally greater amounts of magnesium (50 to 60%) are
reabsorbed in the loop compared with sodium (20 to 25%) or
calcium (30 to 35%). The loop of Henle, specifically the cortical
segment, plays a major role in the determination of magnesium
reabsorption. Of the 10 to 15% of the filtered magnesium that is
delivered to the distal tubule from the loop of Henle, 70 to 80%
is reabsorbed, leaving about 3% of the filtered magnesium
normally appearing in the urine. As there is little evidence for
significant magnesium absorption in the segments beyond the
distal tubule, this portion plays an important role in determining
the final urinary excretion. The cellular mechanisms of magne-
sium absorption within proximal tubule, loop, and distal tubule
are very different and are distinct from calcium, but many of the
controls are similar. This review discusses recent advances in our
understanding of renal magnesium handling and some of the
clinical implications of these observations (Table 1). The discus-
sion is limited to recent observations, as more exhaustive reviews
are available elsewhere [1—31.
PROXIMAL TUBULE
The adult proximal tubule reahsorbs little magnesium and
appears to play a limited role in control of renal magnesium
conservation. Intraluminal magnesium concentration rises along
the proximal tubule as water is reabsorhed so that large concen-
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trations flow into the loop [4—7]. The mechanisms by which
magnesium is reabsorbed within the proximal tubule are not
known, but it is likely to be transcellular as no detectable
magnesium influx could be measured in proximal convoluted or
straight segments perfused with solutions free of magnesium [8,
9]. Extracelluar volume expansion, with an inhibition of proximal
NaCl and water absorption, has little effect on fractional magne-
sium reabsorption [101. Sufficient volume expansion, however,
may affect loop reabsorption leading to increased magnesium
excretion [9, 11].
Magnesium handling in the neonatal proximal tubule may be
quite different than that observed in the adult kidney. This
phenomenon has been overlooked since it was first reported by
Leliéve-Pegorier and colleagues [12]. They showed that luminal
magnesium concentration remained similar to the ultrafilterable
plasma magnesium level along the neonatal rat proximal tubule so
that fractional magnesium absorption was in the order of 60 to
70%, equal to that observed for sodium or calcium. The basis for
the enhanced magnesium reabsorption in the immature nephron
relative to the adult may be a lack of maturation of the paracel-
lular pathway, which would allow significant amounts of magne-
sium to move across with sodium, calcium, and water [12].
Accordingly, in the immature rat magnesium reabsorption is
predominately in the proximal tubule rather than the loop of
Henle. As such, it may be predicted that in young animals control
of magnesium reabsorption is influenced more by factors acting in
the proximal tubule rather than the loop or distal tubule. In
addition, factors influencing magnesium transport in the loop and
distal tubule may be less profound in the young than the mature
nephron because conservation may continue in the proximal
tubule as well as the loop and distal tubule. This notion could be
easily tested with loop diuretics. It would also be interesting to
study young patients with magnesium-wasting diseases such as
Bartter's or Gitelman's syndromes, which are due to mutational
defects in the loop and distal tubule, respectively, to determine if
hypermagnesiuria is as much of a problem as observed in adult
patients [13—15]. Finally, further work is required to determine
the basis and progression of maturation of the proximal paracel-
lular pathway and its importance in renal magnesium handling.
LOOP OF HENLE
Magnesium is principally reabsorbed within the thick ascending
limb (TAL) of the loop of Henle [1, 3]. Using microperfusion
techniques of isolated mouse TAL segments, de Rouffignac and
colleagues have shown that only the cortical thick ascending limb
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Table 1. Summary of major influences that alter renal magnesium
reabsorption
(cTAL) is involved with magnesium reclamation as no transport
was observed in the medullary segment (mTAL) [16]. They have
further demonstrated that magnesium transport is mainly passive
in nature [17], supporting the earlier studies of Shareghi and Agus
[18]. Net magnesium absorption was entirely dependent on the
transepithelial voltage (Fig. 2). With luminal positive voltage,
magnesium moved from lumen into the bath whereas luminal
negative voltage resulted in magnesium secretion into the lumen.
No transport was observed at zero voltage consistent with passive
transport. It is envisioned that magnesium normally moves across
the cTAL epithelium through the paracellular pathway driven by
the positive luminal transepithelial voltage (Fig. 3). Factors
controlling magnesium absorption in this segment act through
changes on the voltage and/or the permeability of the paracellular
pathway (Table 1) [19]. Di Stefano, Mandon, Wittner, de Rouffig-
nac and their colleagues have provided evidence that both ways
are used to physiologically control magnesium reabsorption
within the cTAL [20—24].
Wittner et al have shown that the permeability of the paracel-
lular pathway may be influenced by age and sex so that matura-
tional changes may influence passive transport of magnesium in
the cTAL [25]. As with all cells, intracellular magnesium is
essential for normal cellular metabolism. We have shown that
magnesium enters cTAL cells via selective entry pathways, likely
through Mg2 channels [26]. Whether this cellular transport of
magnesium plays a role in transepithelial absorption is not known;
certainly the majority, if not all, of the magnesium absorption
within the ioop is paracellular [3].
DISTAL TUBULE
The distal tubule normally reabsorbs about 10% of the magne-
sium filtered through the glomerulus [3]. Although this seems like
a small amount, it represents 70 to 80% of the magnesium
delivered to this segment from the loop of Henle. As there is little
magnesium reabsorption beyond the distal tubule in the collecting
ducts, the tubule segments comprising this portion of the nephron
play an important role in determining the final urinary excretion
of magnesium. The role of this nephron segment in the control of
magnesium has been comparatively ignored because of the
greater amounts reclaimed in the loop. However, recent studies
indicate that the distal convoluted tubule may play a more
important role than that recognized previously.
Most of our early knowledge concerning magnesium transport
in the distal tubule has come from micropuncture and microper-
fusion studies of the superficial nephron. Micropuncture studies
showed that significant amounts of magnesium are reabsorbed in
the distal tubule [9, 27—31]. The mammalian distal tubule, located
between the macula densa and the cortical collecting duct, is
comprised of a short post-macula densa segment of thick ascend-
ing limb, the distal convoluted tubule (DCT), the connecting
tubule and the initial collecting tubule. The micropuncture studies
describing distal magnesium absorption may well have included
portions of the superficial connecting tubule and the initial
collecting tubule in addition to the DCT. Magnesium absorption
within each of these individual segments have yet to be studied.
The distal convoluted tubule (DCT) has not been extensively
studied because of its inaccessibility and difficulty in isolation for
in vitro microperfusion studies. Immortalized DCT cell lines have
recently been used to describe cellular magnesium transport
[32—34]. Using the Madin-Darby canine kidney (MDCK) cell line,
which exhibits a distal tubule-like phenotype, we have shown that
magnesium entry is through specific and regulated magnesium
pathways [34]. Electrolyte transport is usually quantitated by
isotopic flux measurements, but as an appropriate isotope for
Mg24 is not available (28Mg has a half-life of 21 hr), a cell model
was developed to assess Mg2 transport using the fluorescent dye,
mag-fura-2, to determine intracellular free Mg2 concentration,
[Mg2]1. Cytosolic free Mg2 concentration of epithelial cells is in
the order of 0.5 mt [34]. This is about 1 to 2% of the total
magnesium, the remainder being complexed to various organic
and inorganic ligands and chelated within the mitochondria
[35—37]. Presumably, it is the free Mg2 that enters into biochem-
ical processes and is transported across plasma membranes. In
order to determine Mg2 transport, the epithelial cells were first
depleted of Mg2 by incubating in magnesium-free culture media.
Subsequently, the cells were placed in solutions containing mag-
nesium and [Mg2] measured as a function of time over the
duration of Mg24 influx (Fig. 4). The rate of concentration
change, d([Mg2])/dt, is an estimate of transport rate. Influx of
Mg2 is concentration-dependent so that the rate of Mg2
transport increases with external Mg2' until saturation is attained
at about 0.5 mvt [32]. Mg24 influx into Mg2 '-depleted cells was
inhibited by Mn2 and La3 and by dihydropyridine channel
blockers such as nifedipine. Ca2 neither blocked Mg2 entry nor
was 45Ca uptake or [Ca2], intracellular free Ca2, changed in
the presence of Mg2-depletion or the Mg2-refill process [32].
These results suggest that the influx pathway is specific for Mg2
and not shared by Ca2. We used this approach to characterize
the cellular mechanisms of Mg2 uptake in an established mouse
distal convoluted tubule (MDCT) cell line. This cell line was
originally isolated from mouse distal tubules and immortalized by
Pizzonia et a! [38]. MDCT cells exhibit many of the functional
properties characteristic of the in vivo distal convoluted tubule,
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Fig. 1. Summary of segmental magnesium
absorption along the nephron relative to
sodium and calcium reabsorption.
Fig. 2. Magnesium net fluxes (JMg) measured in absence of active NaCI
transport (lumen, io— M furosemide) in mouse cTAL segments. V1 indicates
the transepithelial voltage, lumen with respect to bath. Flux-voltage relation-
ships were measured in two experimental series: (1) with symmetrical
solutions in lumen and bath (150 mtvi NaCI, solid circles); (2) in presence of
hyposmotic luminal solutions (lumen, 50 mM NaCI; bath, 150 mM NaCI),
generating positive dilution voltages (open circle in top right quadrant); and
(3) with symmetrical solutions in lumen and bath (150 ms NaC1, solid circles)
and in presence of a bath solution in which NaC1 concentration was less than
the luminal perfusate (lumen, 150 mtvi NaCI; bath, 50 mrvt NaCl + 200 ms
mannitol), generating negative dilution voltages (open circle in bottom left
quadrant). Data from di Stefano et al [171.
such as amiloride-inhibitable Na transport, chlorothiazide-sen-
sitive NaCI cotransport and parathyroid hormone (PTH)- and
calcitonin-stimulated Ca2' transport [391.
Our initial studies looked at the changes in Mg2 entry into
MDCT cells following alterations in membrane voltage [32]. In
these studies, with the same starting [Mg2]1 and the same
external Mg2 concentration, the more negative the membrane
voltage, that is, hyperpolarization, the higher the magnesium
influx rate. Conversely, depolarization of membrane voltage di-
minishes Mg2 uptake. The dependence of magnesium entry on
the driving force induced by the electrochemical gradient indi-
cates that cellular Mg2 entry may be mediated by an ion channel.
As the distal tubule is characterized by a negative luminal
transepithelial voltage and high epithelial resistance, it is con-
cluded that magnesium transport is active and transcellular in
nature. The pathways involved with transcellular Mg2 absorption
are schematically illustrated in Figure 5. The evidence is that
magnesium moves passively into the cell across the luminal
60% 15%
100% 100%
Mg CaINa Thin
descending
limb
no,/0
3% 1%
Mg, pmoImin-1mm1
0.8
0.6
0.4
Cell
0.2
Lumen
Furosemide Na
2C1
PD +8mV
Na --
Blood
Na
0 mV
6 9 12 15 18
mV Mg2 0.25 mM
(8) —0.6
—0.8
Na Ca2 Mg2
0.75 mM
Fig. 3. Schematic model of magnesium absorption in thick ascending
limb of Henle's loop. Conductive pathways are denoted by dashed arrows
and carrier-mediated transport by solid arrows. Active transport processes
are indicated by symbol. Modified from Quamme [11.
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Fig. 4. Intracellular free Mg2 concentration in normal and Mg2-
depleted Madin-Darby canine kidney (MDCK) cells. Confluent MDCK
cells were cultured in either normal (0.6 mrvi Mg2) or Mg2tfrcc media
(<0.01 mM) for 16 hours. Fluorescence studies were performed in buffer
solutions in absence of Mg2, and, as indicated, MgCI2 (5.0 m final
concentration) was added to observe changes in intracellular Mg2
concentration. The buffer solutions contained (in mM): 145 NaCI, 4.0 KCI,
0.8 K2HPO4, 0.2 KH2PO4, 1.0 CaCI,, 5.0 glucose, and 10 HEPES/Tris, pH
7.4. Fluorescence was measured at 1 data point/second with 25-point
signal averaging, and the tracing was smoothed according to methods
previously described. Data from Quamme and Dai 1341.
membrane driven by a favorable transmembrane voltage. The
luminal magnesium concentration in the distal tubule is in the
order of 0.2 to 0.7 m, depending on the condition studied, and
intracellular free Mg2 is about 0.5 m. Thus, under some
circumstances Mg2 entry is against an appreciable concentration
gradient [40]. We speculate that Mg2 entry is through a unique
channel and transport is dependent on the transmembrane volt-
age. The active step in transcellular movement is predicted to be
at the basolateral membrane where Mg2 leaves the cell against
both electrical and concentration gradients. The means by which
Mg2 actively moves across the basolateral membrane is un-
known. Evidence taken from studies using nonepithelial cells
suggest that a Na-Mg2 exchange may occur; Na moving back
into the cell coupled with Mg2 exits from the cell into the
interstitium [41, 421. In this view, the factors that influence
transcellular magnesium absorption include alterations of the
entry step at the luminal membrane and changes in activity of the
exit step at the basolateral membrane. As with other ions, it is
likely that the entry step is rate-limiting and controls transepithe-
hal magnesium reabsorption in DCT cells.
HORMONAL CONTROL OF RENAL MAGNESIUM
REABSORPTION
A large number of hormones have been implicated in the
control of renal magnesium conservation. Extensive description of
hormone actions have been reviewed elsewhere [1—3]. Parathyroid
hormone (PTH), calcitonin, glucagon, and vasopressin (AVP)
stimulate magnesium absorption in both the TAL [9, 24, 31,
43—48] and DCT [9, 11, 27, 28, 46, 47, 49]. Insulin increases
magnesium absorption in mouse cTAL; the effects of this hor-
mone in the DCT have not been studied [22]. Finally, steroid
hormones influence NaCI and magnesium absorption within the
TAL [50—52] and DCT [51, 53]. All of these hormones stimulate
magnesium absorption in the TAL and DCT by very different
cellular mechanisms.
Thick ascending limb
Receptors for PTH, calcitonin, glucagon, AVP, and the 13-
adrenergic agonists such as isoproterenol are coupled to adenyl-
ate cyclase in the TAL [54—571. In addition, these receptors likely
are also coupled to other signaling pathways that may be interac-
tive with cAMP-mediated actions [3, 58]. Shareghi and Agus
microperfused rabbit cTAL segments and measured magnesium
fluxes following addition of PTH to the bath [18]. They showed
that magnesium absorption was stimulated in the absence of
changes in transepithelial voltage. Using mouse cTAL segments,
Wittner and colleagues showed that all of the above hormones
enhanced both transepithelial voltage and magnesium absorption
(Fig. 6) [24, 48]. However, the stimulation of magnesium transport
was not proportional to the voltage change. The latter results led
these investigators to conclude that hormonal actions in the
mouse cTAL resulted from both a rise in transepithelial voltage
and an increase in magnesium permeability of the paracellular
pathway.
The cellular mechanisms underlying hormone-induced increase
in transepithelial voltage have been clarified by Greger, Bleich
and Schlatter [59] and Reeves and Andreoli [60]. Receptor-
mediated activation of basolateral membrane C1 conductance
and apical Na-2CL-K cotransport/K' conductance increases
the luminal positive voltage. These hormones also increase the
paracellular permeability but the mechanisms are not clear. de
Rouffignac postulates that hormonal control of paracellular path-
way proteins, possibly through phosphorylation, may change the
permeability and allow for a greater movement of magnesium
across the epithelium from the lumen to the interstitium [3].
Further studies are necessary to define the molecular mechanisms
involved with this control.
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Fig. 5. Schematic model of magnesium absorption in the distal convo-
luted tubule. Conductive pathways and carrier-mediated transport are
denoted by solid arrows. Active transport processes are indicated by -
symbol. The sites of action of the transport inhibitors; dihydropyridines(such as nifedipine), thiazides, and amiloride are indicated.
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Fig. 6. Individual effects of peptide hormones
on net magnesium transport in isolated thick
ascending limb segments. Isolated segments of
either cortical (cTAL) or medullary (mTAL)
thick ascending limbs (panels A and B,
respectively) of mouse nephrons were
microperfused at 2 nI/mm in absence (c,
control) and presence of arginine vasopressin
(AVP; lO'° M), glucagon (GLU; synthetic
porcine glucagon, 1.2 x 108 vi), calcitonin
(HCT; synthetic human ealcitonin, 3 X lO M),
parathyroid hormone (PTH; bovine, I to 34
fragment, iO M), isoproterenol (ISO; iO M),
or insulin (INS; iO M). Hormones were
added to bath solutions. *signiflcance from
preceding period. Data are from Bailly et al
[54], Mandon et al [22], and Wittner et al [24,
48].
In addition to hormones acting through Ga-coupled proteins,
Mandon et al have reported that insulin increases transepithelial
voltage and stimulates magnesium absorption in perfused mouse
cTAL segments [22]. Accordingly, signaling pathways involving
tyrosine kinases may also be involved in changes in voltage and
paracellular pathway permeability. Further studies are needed to
define the individual receptor-mediated pathways and their inter-
actions that are involved with hormone-stimulated magnesium
transport in the TAL.
In all of the above in vitro studies performed by Bailly, Di
Stefano, dc Rouffignac, and Wittner and colleagues, no magne-
sium absorption was observed in the mTAL (Fig. 6). Their
conclusions indicate that the passive permeability of the mouse
mTAL to divalent cations is very low and not influenced by AVP
[23]. There may be species differences so that in some instances
magnesium may be absorbed in the medullary segment of the
TAL.
The evidence suggests that steroid hormones augment NaCI
absorption and transepithelial voltage in isolated TAL segments
[50, 52]. Although there have been no direct studies of the effects
of mineralocorticoid on TAL magnesium transport, the increment
in voltage would be expected to lead to an increase in magnesium
absorption. However, chronic hyperaldosteronism leads to extra-
cellular volume expansion and diminished salt absorption in the
TAL [61]. This is associated with elevated urinary magnesium
excretion [62]. Salt restriction and normalization of the extracel-
lular volume mitigates aldosterone-induced hypermagnesuria
[63]. In summary, the effects of steroid hormones within the TAL
are complex; akiosterone enhances salt and probably magnesium
retention that leads to volume expansion that in turn leads to
increased salt and magnesium excretion.
Distal tubule
Adenylate cyclase-coupled hormone receptors are present
along the distal tubule including the DCT [56, 57]. Studies have
shown that there are apparent species differences in receptor-
mediated adenylate activity, and as for the cTAL there are
probably other receptor-mediated signaling pathways in addition
to cAMP-dependent processes [64—67]. These pathways are not
well defined at the present time. The early micropuncture studies
showed that PTH, calcitonin, and glucagon increased magnesium
absorption in the distal tubule, hut they did not discern the
cellular mechanisms involved [9, 11, 27, 28, 31, 45, 47, 49]. As
magnesium absorption in the distal tubule is transcellular and
active in nature, hormones act within the cell on active transport
rather than passively through the paracellular pathway.
Recent studies have shown that PTH, calcitonin, glucagon, and
AVP stimulate Mg2 uptake into MDCT cells (personal observa-
tion; Fig. 7). As these hormones also stimulate cellular cAMP
accumulation, we determined whether cAMP may influence
Mg2 entry into MDCT cells. The addition of cAMP increased
Mg2 uptake whereas inhibition of protein kinase A prevented
hormone-stimulated uptake [68]. Accordingly, receptor-mediated
cAMP release and activation of protein kinase A plays a role in
hormone-stimulated Mg2 uptake in MDCT cells. Other signal-
ing pathways may also he involved in control of magnesium
transport in the distal tubule [65—67]. The cellular mechanisms
whereby cAMP and protein kinase A activation enhance Mg2
entry is unclear.
Mineralocorticoid receptors are present in DCT cells that are
thought to be involved in expression of NaC1 cotransport, Na
conductance, and sodium pump activity [69]. The effects of
aldosterone on magnesium transport with the intact distal tubule
have not been studied. We have studied the effects of aldosterone
on Mg2 entry into MDCT cells [53]. Incubation of aldosterone,
10 M, for 16 hours prior to the determination of Mg2 uptake
failed to have any effect on basal magnesium transport. However,
pretreatment of MDCT cells with aldosterone potentiated gluca-
gon- and AVP-stimulated Mg2 uptake (Fig. 8).
The explanation for these observations may be based on the
1184 Quamme. Renal magnesium transport
INSHOT
HOT
b
E
0
E0
Co
ci)
><
ci)z
Aj 2+Mg AVP
AVP
1.6
1.2
0.8
0.4
0
—0.4
PTH
ISO
GLU
GLU
CO
ISO
INS
00
+*
cb,220 rj *
#1 *
1180 'I
a
?140
100 i&L_ -— - _____ -
Control cAMP Glucagon AVP GLU and AVP
+
+
300
260
220
& 180
m
a
? 140
100
*
Control Aldo Glu Aldo AVP Aldo
and Glu andAVP
Quamme: Renal magnesium transport 1185
Fig. 7. Hormonal stimulation of Mg2 uptake in Mg2-depIeted mouse
distal convoluted tubule (MDCT) cells. The studies were performed
according to methods given in legend to Figure 4 but with the addition of
1.5 mM MgCI2. The mean Mg2 uptake rate, d([Mg2]1/dt, was determined
as the change in Mg2 concentration with time over the first 200 seconds
of study. 8-bromo cAMP, i0 M, glucagon, iO M, and arginine
vasopressin, iO M, were added the buffer solution where indicated.
Values are means SE, N = 5 to 10 cells. *Significant from control values
and significant of glucagon plus AVP vs. either glucagon or AVP alone.
Data are from Dai et al [68].
observation that mineralocorticoids enhance hormone-stimulated
cAMP generation in epithelial cells. For instance, adrenal insuf-
ficiency is associated with impairment of urinary diluting and
concentrating capacity [70, 71; reviewed in 72]. Rajerison et al
demonstrated that adrenalectomy reduced vasopressin-stimulated
adenylate cyclase activity in membrane fractions prepared from
rat kidney medulla [71]. Doucet et al have shown that glucagon-
and AVP-responsive cAMP generation is diminished in thick
ascending limb and collecting tubule segments harvested from
adrenalectomized rats compared to animals treated with physio-
logical doses of aldosterone [72, 73]. These investigators postulate
that aldosterone induces a protein(s) that stimulates hormone-
sensitive adenylate cyclase activity. Studies with kidney membrane
fractions and isolated segments demonstrated that an impairment
of coupling between hormone receptors and adenyl cyclase cata-
lytic units was responsible for diminished cAMP generation in the
absence of aldosterone [73]. The mechanism(s) through which
steroids control G5 proteins (synthesis and/or degradation vs.
activity of each unit) is not known [72]. Our studies with MDCT
cells suggest that aldosterone potentiates glucagon- and AVP-
stimulated cAMP generation in distal convoluted tubule cells [53].
This was associated with an increase in Mg2 entry rate in
response to these hormones. Aldosterone also induces an increase
in Na conductance and sodium pump activity among other
metabolic changes [69]. Further research is warranted to deter-
mine the involvement of these changes in hormone-mediated
control of Mg2 transport. As mentioned above, mineralocorti-
coid excess with extracellular fluid volume expansion results in
increased urinary magnesium excretion as well as salt excretion
[63].
Multihormonal control of renal magnesium reabsorption
The above list of hormones is far from exhaustive and further
research will in all likelihood identify others that affect renal
Fig. 8. Aldosterone potentiates glucagon. and AVP.stimulation of Mg2
entry in MDCT cells. MDCT cells were incubated with and without
aldosterone (Aldo.), iO M, for 16 hr prior to the determination of Mg2
uptake. Glucagon or AVP, iO M, was added where indicated. The rate
of Mg2* influx as determined by d([Mg2]1)/dt was measured with the
given hormone concentrations using fluorescence techniques performed
according to those given in legend to Figure 4. Values are means 5E for
3 to 6 cells. *signiflcant from control values and + significance of glucagon
+ Aldo. or AVP + Aldo. versus glucagon or AVP, respectively. Data are
from Di et al [53].
magnesium handling [31. There appears to be no single hormone
that controls renal magnesium balance, rather many hormones act
in concert to regulate magnesium. Elalouf et al have shown that
glucagon and vasopressin are additive in promoting magnesium
absorption within the cTAL whereas Mandon et al and Elalouf et
al reported that insulin potentiates the actions of vasopressin [22,
45]. Moreover, many of the hormones interact to control magne-
sium transport. In the distal tubule, glucagon and AVP are
additive or, as we have seen with aldosterone, potent in their
effects on hormone stimulation of magnesium reabsorption (Figs.
7 and 8) [45, 74]. Individual hormonal control of magnesium
conservation may be important in specific instances. For instance,
PTH and calcitonin are principally involved in the regulation of
calcium balance. The conservation of magnesium with calcium
may facilitate calcium deposition. A further example is glucagon.
A protein meal is a potent stimulus for glucagon secretion.
Elevated circulating glucagon concentration contribute to the
disposal of nitrogen metabolites, amino acids, and elevation of
GFR [75]. Glucagon may be important in magnesium conserva-
tion following protein ingestion because of its associated increase
in GFR and filtered magnesium. Additionally, stimulation of ioop
and distal magnesium conservation by AVP may be necessary to
maintain normal magnesium balance when salt and water flow in
the DCT is reduced during antidiuresis. Finally, mineralocorticoid
potentiation of AVP actions may be necessary to maintain normal
Mg2 balance when salt and water flow in the distal tubule is
reduced during aldosterone-mediated antidiuresis. Mineralocor-
ticoid potentiation would increase AVP-stimulated Mg2 reab-
sorption commensurate with enhanced salt and water retention.
Perhaps the multihormonal control of renal magnesium absorp-
tion is a more efficient way of maintaining magnesium balance
than what would be expected with a dedicated hormone.
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PLASMA MAGNESIUM AND CALCIUM CONTROL RENAL
MAGNESIUM REABSORPTION
Thick ascending limb
Elevation of plasma magnesium or calcium concentration in-
hibits magnesium and calcium reabsorption, leading to hyperma-
gnesiuria and hypercalciuria. Inhibition of reabsorption occurs
within the cTAL segment of the loop of Henle where both
magnesium and calcium are reabsorbed primarily by passive
mechanisms [9, 18, 23, 761. The simplest explanation was that
elevation of magnesium or calcium decreased the permeability for
these cations in the paracellular pathway, so that for any given
transepithelial voltage there is less magnesium and calcium ab-
sorption. In support of this notion, Di Stefano et al perfused
isolated rabbit cTAL segments and reported an increase in
transepithelial resistance by about 50% with an increase of
luminal or bath magnesium and calcium of 2.5 to 10 mrvi [76].
However, this does not explain our earlier observations indicating
that magnesium and calcium act only from the peritubular or
blood side and not the luminal side [1, 9j. In vivo microperfusion
of rat TAL segments clearly showed that increases in luminal
magnesium concentrations were associated with increases in
magnesium absorption rates [91 Intraluminal magnesium or
calcium did not inhibit either magnesium or calcium absorption
[77]. However, elevation of plasma magnesium or calcium, that is,
on the basolateral side of the TAL, resulted in inhibition of both
magnesium and calcium absorption [9, 77]. The explanation for
the asymmetrical actions of elevated magnesium and calcium
across the TAL epithelium was not evident at the time that these
studies were performed. The recent identification of a Ca247
Mg2-sensing receptor located on the peritubular side of TAL
cells explains this phenomenon [78, 79].
A Ca2 /Mg2-sensing receptor has been found in glomeruli,
proximal tubules, cortical and medullary thick ascending limbs,
distal convoluted tubules, cortical collecting ducts, and outer
medullary collecting ducts [80]. This receptor was first cloned
from the bovine parathyroid gland [78]. The cDNA encodes a G
protein-coupled receptor that is involved with control of parathy-
roid hormone (PTH) secretion. The eDNA sequence suggested
that the receptor is comprised of three major domains: (1) a large
extracelluar amino-terminal domain of 613 amino acids that is
thought to possess the cationic binding sites; (2) a 250 amino acid
domain with seven predicted membrane-spanning segments char-
acteristic of the superfamily of 0 protein-coupled receptors; and
(3) a carboxyl terminal domain of 222 amino acids that likely
resides within the cytoplasm and is involved with intracellular
signaling processes [791. The renal receptor is very similar to the
one found in the parathyroid gland [811. The evidence is that Ca2
or Mg2 binds to the extracelluar domain initiating a number of
intracellular signals. Among other things, stimulation of
proteins modulate adenylate cyclase activity and cAMP levels and
Gq proteins activate phospholipase C releasing inositol 1,4,5-
trisphosphate, cytosolic Ca2 and cytochrome P-450 metabolites
[79, 82, 83]. Ca217Mg2-sensing receptor mediated intracellular
signaling pathways have important effects on cellular function [79,
84]. Using immunocytochemistry, Riccardi and colleagues have
shown the receptor is localized to the luminal membrane of
proximal tubules and the inner medullary collecting ducts and to
the basolateral membrane of cTAL and mTAL cells (data pre-
sented at the 1997 ASN). The site and location of the Ca2 4/Mg2 -
sensing receptor(s) have important effects on renal magnesium
handling. Wang and Hebert reported that basolateral receptor
activation inhibits apical K channels and possibly Na-2C1-K
cotransport in the rat TAL [83]. This inhibition would be expected
to diminish transepithelial voltage and, in turn, passive transport
of sodium in the mTAL and sodium, magnesium, and calcium
within the cTAL leading to increased distal delivery of these
electrolytes. Elevation of divalent cations in the medullary collect-
ing duct activates the luminal Ca2/Mg2-sensing receptor that
diminishes water permeability and inhibits volume reabsorption
[84]. The net effect is to increase volume flow along with an
increase in calcium and magnesium excretion. The notion ad-
vanced by Sands et al is that a concomitment increase in volume
flow with inhibition of calcium and magnesium reabsorption
would minimize the incidence of stone formation [85]. It is clear
from these studies that the presence of a Ca2/Mg2-sensing
receptor in the TAL allows for an additional control of renal
magnesium absorption.
Clearance studies have suggested that renal magnesium reab-
sorption is a Tm-limited process, that is, the kidney possesses a
tubular maximum for transport that can be saturated with eleva-
tions of plasma magnesium [63, 86]. Determination of the Tm
value as been useful in assessment of renal magnesium conserva-
tion [86, 87]. Micropuncture studies have shown that this phe-
nomenon is due to segmental differences in magnesium absorp-
tion [11]. The cellular basis for a Tm is inhibition of magnesium
transport within the loop of Henle [1, 9]. It is likely that activation
of a Ca2/Mg2-sensing receptor within the thick ascending limb
plays a role in this Tm phenomenon.
Distal tubule
The Ca2'7Mg2-sensing receptor has been localized by immu-
nocytochemical techniques along the entire length of the distal
tubule [80]. The receptor was found on the basolateral membrane
of the DCT but was less abundant than that of the TAL
(presented by Riccardi Ct al at the 1996 ASN). The function of the
Ca2/Mg2-sensing receptor within the distal tubule is not fully
known. The Ca2/Mg2 -sensing receptor is present in the MDCT
cell line so that studies may be performed to determine its role in
this segment [88]. The concentrations of extracellular Ca2 or
Mg2 that activate this receptor are in the order of 0.2 to 3.0 ms,
which is appropriate for physiological responses. Interestingly,
either Ca2 or Mg2 may activate the receptor in the presence of
high levels of extracellular Ca2 or Mg2 [88]. More recently, we
have shown that activation of the Ca2/Mg2-sensing receptor
does not inhibit basal Mg2 entry in MDCT cells but it does
inhibit hormone-stimulated Mg2 uptake [89]. As receptor acti-
vation with neomycin, Ca2 or Mg2 also inhibits PTH-, calcito-
ni, glucagon-, and AVP-stimulated cAMP release, it was con-
cluded that the receptor diminishes hormone-stimulated Mg2
uptake through inhibition of hormone-induced cAMP generation.
It is inferred that the Ca2/Mg2-sensing receptor plays an
important role in hormonal regulation of magnesium absorption
in the DCT [89].
Diseases involving the Ca2/Mg2 -sensing receptor
It has been shown that both inactivating and activating muta-
tions of the Ca2/Mg2-sensing receptor are found in clinical
medicine [90, 91]. Two rare hypercalcemia disorders, familial
hypocalciuric hypercalcemia (FHH) [92—95] and neonatal severe
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hyperparathyroidism (NSHPT) result from inactivating mutations
when present in the heterozygous and homozygous states, respec-
tively [96, 97]. The renal excretion of both calcium and magne-
sium is reduced in these patients leading to hypercalcemia and in
some instances to hypermagnesemia [92—951. As reviewed by
Hebert, defective extracellular Ca2 tIMg2
-sensing likely results
in inappropriate absorption of calcium and magnesium in the
TAL and possibly other segments leading to diminished excretion
and elevated plasma levels [821. A knockout mouse model has
been developed with all of the characteristics of FHH and NSHPT
supporting this idea [98]. On the other side, an autosomal-
dominant inherited activating mutation has also been reported
that was associated with hypocalcemia and hypomagnesemia in
about half the patients, presumably due to inappropriate renal
wasting [91, 99]. It would be interesting to determine the effects of
amiloride, a renal-conserving diuretic, in these patients to see if
renal magnesium-wasting could be ameliorated.
INTRINSIC CELLULAR CONTROL OF RENAL
MAGNESIUM REABSORPTION
All of the above receptor-mediated controls also influence
calcium and sodium reabsorption in the TAL and calcium absorp-
tion in the DCT. What then selectively controls renal handling of
magnesium? It has been recognized clinically for many years that
diminished dietary magnesium intake or intestinal malabsorption
leads to appropriate renal magnesium conservation in an effort to
maintain magnesium balance [100—102]. This response is sensitive
and independent of renal sodium and calcium excretion. The basis
for this alteration in magnesium transport is not fully understood.
However, it is clear that the fall in renal magnesium excretion is
not simply due to a drop in plasma and filtered magnesium
because a number of clinical studies have reported diminished
urinary magnesium excretion with normal serum magnesium
concentrations. In support of these clinical observations, we
performed studies [40] in rats pair-fed control magnesium diets
(0.05% Mg2SO4) and magnesium-restricted diets (< 0.01% Mg).
Fractional urinary magnesium excretion of magnesium-restricted
rats fell from 17 3% to 8 1% within eight hours without a
change in plasma magnesium concentration. Accordingly, this
cellular adaptation is rapid (detected within 2 hr), specific (with-
out effect on sodium and calcium reabsorption), and sensitive
(without detectable changes in plasma magnesium concentration).
Micropuncture [40] and microperfusion [1031 studies demon-
strated that the cellular adaptation occurred within the thick
ascending limb and the distal tubule. This ability to adjust
transport appears to be intrinsic to renal cells. In summary, no
extrinsic hormone controls renal magnesium transport separate
from sodium and calcium handling. Rather, we believe that
epithelial cells appropriately "adapt" their transport rate accord-
ing to the availability of magnesium. This notion has received
further support with in vitro microperfusion studies of eTAL
segments and investigations using isolated distal tubule cells [26,
32, 34].
Thick ascending limb
de Rouffignac and colleagues have recently shown that magne-
sium absorption is increased in cTAL segments harvested from
dietary magnesium- deprived mice compared to control animals
[103, personal communicationi. Their studies showed that in-
creased absorption was due to an increase in permeability of the
paracellular pathway for magnesium that enhances magnesium
movement at any given transepithelial voltage. Again, the incre-
ment in magnesium transport in the loop was entirely passive in
nature.
Distal tubule
We showed that isolated distal tubule cells, either MDCK or
MDCT, cultured in magnesium-free media increased their Mg2
transport rate [32, 34]. This response is rapid (within I to 2 hr),
and specific for magnesium as there was no effect on sodium or
calcium transport. The "adaptation" of magnesium transport rates
is intrinsic as there were no hormones in the culture media (Fig.
2). Furthermore, the adaptation was dependent on the concen-
tration of media magnesium and the length of time in the culture
media [26].
The response of epithelial cells to magnesium-free culture
media is rapid; it is detectable within one to two hours. The
increase in Mg2 refill rate is not maximal until —four to six
hours. This suggests that in addition to increasing the entry rate
there may also be recruitment of new or formed transporters into
the apical membrane. To test this possibility we pretreated MDCT
cells with either actinomycin D, an inhibitor of transcription, or
cycloheximide, an inhibitor of protein synthesis. These inhibitors
led to a decrease of about 50% in the adaptive response as
measured by Mg2 refill rate in Mg2-depleted cells (unpublished
observations). From these studies, we infer that Mg21 -depletion
results in genetic expression of new proteins that are involved in
the adaptative response leading to enhanced Mg2 uptake. Fur-
ther studies are necessary to characterize the gene product(s)
involved and the turnover of the components known to be
important in up-regulation of Mg2 transport.
In summary, these studies with isolated distal cells support the
notion of intrinsic controls within the cells that adapt their
magnesium transport rate appropriately to the environmental
magnesium. We postulate that this intrinsic adaptation provides
the discriminatory control of magnesium transport independent
of sodium and calcium. Intrinsic adaptation provides the selective
control that hormonal regulation does not have. These studies
with isolated cells are in keeping with the experimental observa-
tions within intact kidney [40].
Diseases involving intrinsic cellular control of renal magnesium
reabsorption
A practical use of this property of renal cells to adapt to
magnesium availability is the clinical assessment of magnesium
homeostasis. As most of the magnesium within the body is
intracellular, determination of plasma magnesium may not reflect
magnesium status [104]. Some clinical laboratories use magne-
sium retention following parental administration of magnesium
salts [105, 106], and others measure mononuclear blood cell or
platelet magnesium levels to assess magnesium status [102, 107—
109]. These approaches are not particularly useful in the routine
laboratory. As described above, the kidney is very sensitive to
magnesium, so that urinary magnesium excretion relative to the
plasma concentration reflects magnesium status. Accordingly, the
simplest test is to evaluate renal magnesium physiology. This can
he done by collecting a 24-hour urine specimen and calculating a
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24-hour magnesium clearance [104]. This of course holds true
only in the absence of renal disease.
Familial hypomagnesemia due to renal magnesium-wasting is
an uncommon disease [110, 111]. The MEDLINE lists over fifty
case reports in the last decade and it is probable that many
presentations go unreported. Familial magnesium-wasting disease
is by all accounts an autosomal recessive disease [112—116].
However, one study reported dominant penetrance [117]. The
complexity of the clinical reports suggest that familial hypomag-
nesemia may be a spectrum of genetic diseases [118—123]. It is
often associated with hypercalcemia and at times with hypokale-
mia [112, 115, 122—124]. Amiloride may be beneficial in some
cases but not in others [110, 118]. Renal magnesium-wasting may
be due to defective transport in the thick ascending limb or the
distal tubule resulting in the complexity of presentation. Muta-
tions of transport proteins or regulatory elements controlling
transport are likely to be basis for these familial diseases. We have
recently identified a gene using differential display of amplified
cDNAs from MDCK cells grown in low magnesium [125]. The
message for this gene, termed the magnesium-responsive element,
is enhanced in magnesium-deficient DCT cells. Furthermore,
transfection of MDCK cells with antisense oligonucleotides of this
response-element prevented the up-regulation of Mg2 entry
expected with low magnesium. Further studies are underway to
define its role in normal control of magnesium transport. Changes
in expression of this gene could well provide the basis for altered
renal magnesium handling.
DIURETICS
Thick ascending limb
Loop diuretics, such as furosemide and bumetanide, diminish
salt absorption in the TAL by virtue of their action on electro-
neutral Na-2C1-K cotransport across the luminal membrane [59,
60]. Inhibition of luminal Cl entry leads to diminished cellular
C1 activity and diminished basolateral conductive CL efflux,
which results in a decrease in lumen-positive voltage [17]. It has
been postulated that the lumen-positive voltage provides the
driving force through the paracellular route for 40 to 50% of the
total net sodium absorption. Magnesium, a divalent cation, may
be influenced to a greater degree than the monovalent cations,
such as sodium and potassium. This notion is supported by our in
vivo microperfusion findings illustrating that net magnesium
transport is inhibited to a greater degree than sodium at any given
luminal furosemide concentration [30]. The observation of frac-
tionally greater inhibition of TAL magnesium absorption com-
pared with sodium is relevant to the management of patients
receiving loop diuretics because hypomagnesemia is a possible
complication of diuretic therapy.
Distal tubule
The distally acting diuretics, amiloride and chlorothiazide stim-
ulate magnesium reabsorption within the distal convoluted tubule.
A large number of clinical studies have led to the notion that
amiloride possesses magnesium-conserving properties in addition
to its natriuretic and potassium-sparing effects [118, 126]. Despite
these observations very few experimental studies have been
published concerning amiloride effects on renal magnesium han-
dling. Devane and Ryan have shown that infusion of amiloride
reduced the fractional excretion of magnesium in anaesthetized
Fig. 9. Effect of amiloride or chiorothiazide on Mg2 influx into normal
and Mg2-depleted MDCT cells. Fluorescence was measured according to
techniques illustrated in Figure 4. Amiloride or chiorothiazide (CTZ) at
final concentrations of iO— M were added from stock solutions where
indicated. Tracings are representative of 6 studies. Data are from Dai et
al [32, 333.
rats, which they attributed to a direct renal action of the drug
[127]. The nephron segments and cellular mechanisms were not
delineated in this study.
We determined the cellular effects of amiloride on Mg2
uptake in isolated MDCT cells [32]. Amiloride stimulated ni-
fedipine-sensitive Mg2 influx by 41 3% (Fig. 9). Amiloride
blocks Na entry into DCT cells and hyperpolarizes the cell by
—28 8 mV [128]. As amiloride does not stimulate Mg24 uptake
in the absence of a change in voltage, we concluded that it acts
through hyperpolarization of the membrane voltage, thereby
increasing the driving force for Mg2 entry [32]. These findings
provide the basis for both clinical and experimental observations
that show that amiloride is a magnesium-conserving diuretic [127,
129, 130].
Thiazides are extensively used in the management of diseases
due to fluid retention, diabetes insipidus, and nephrolithiasis.
Despite their widespread use, little is known about the actions of
thiazides on cellular magnesium transport. Some studies have
reported that patients receiving chiorothiazide may develop mag-
nesium deficiency due, most likely, to renal magnesium-wasting
[126, 131].
Recent studies with isolated MDCT cells have shown that
chlorothiazide increases Mg2 uptake in a dose-dependent fash-
ion (Fig. 9). Maximal concentrations (10- ' M) of chlorothiazide
increased Mg2 transport by 58% [33]. This was associated with
hyperpolarization of the plasma membrane voltage from —65 5
to —80 5 mV. Inhibition of Na-Cl cotransport and diminished
intracellular sodium and chloride concentration results in hyper-
polarization of the apical membrane of the distal convoluted
tubule cells [132, 133]. An increase in the membrane voltage
enhances Mg2 + uptake into MDCT cells. Accordingly, chlorothi-
azide may stimulate Mg2 transport through changes in the
membrane voltage similar to the basis of amiloride actions. The
studies with MDCT cells demonstrate that chlorothiazide en-
hance Mg2 entry in distal convoluted tubule cells. It is inferred
that enhanced influx would translate into an increase in magne-
sium reabsorption and diminished urinary magnesium excretion.
The clinical use of thiazide diuretics in patients over a long
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period of time sometimes lead to hypomagnesemia, probably
from renal magnesium-wasting [130, 134—1371. Chlorothiazide
inhibits Na-Cl cotransport, leading to an increase in urinary NaCI
excretion and contraction of the extracelluar fluid volume. The
renin-angiotensin system is activated, resulting in elevated aldo-
sterone levels and increased potassium and hydrogen ion secre-
tion, which in turn may result in hypokalemia and exacerbation of
metabolic alkalosis. Volume depletion, elevated aldosterone, and
metabolic alkalosis increase renal magnesium conservation so that
it is unlikely that these influences would lead to magnesium-
wasting [1041. However, hypokalemia has been associated with
altered renal magnesium handling [115, 138—1401. Using MDCT
cells, it was shown that cellular potassium depletion may inhibit
Mg2 influx (see below). We postulate that chronic use of
thiazides may result in potassium-depletion leading, in turn, to
renal magnesium-wasting.
METABOLIC ACIDOSIS AND ALKALOSIS
It has long been known that systemic acidosis is associated with
renal magnesium-wasting. Acute metabolic acidosis produced by
infusion of NH4CI or HC1 leads to significant increases in urinary
magnesium excretion [63, 141]. Chronic acidosis also leads to
urinary magnesium-wasting that, as with acute acidosis, may be
partially corrected by the administration of bicarbonate [142, 143].
In contrast to metabolic acidosis, acute and chronic metabolic
alkalosis consistently leads to a fall in urinary magnesium excre-
tion [1441.
Although it has long been known that metabolic acidosis and
alkalosis alter renal magnesium handling, relatively little informa-
tion is available regarding the tubular segment involved. Wong,
Quamme and Dirks showed that metabolic alkalosis resulted in
increased magnesium reabsorption in the loop of Henle and distal
tubule of the dog [1451. Magnesium reabsorption was closely
associated with bicarbonate delivery to the distal tubule in this
study. We have shown that acute bicarbonate infusions into
chronic acidotic rats leads to a marked increase in magnesium
reabsorption in the ioop and distal tubule [1431. Thus, on balance,
the evidence is that metabolic acidosis and alkalosis act within
both the loop of Henle and the distal tubule.
Thick ascending limb
Di Stefano et al perfused isolated mouse cTAL segments
harvested from mice maintained on alkaline drinking water (20
m sodium bicarbonate) for three days [1031. They showed that
alkalosis doubled magnesium absorption from control levels of
0.47 0.06 to 0.89 0.06 pmol min mm' without a change
in transepithelial voltage. They interpreted this data to indicate
that alkalosis changes the permeability of the paracellular path-
way so that magnesium moves passively through the pathway to a
greater degree, resulting in greater magnesium absorption. The
effects of metabolic acidosis were not determined in this study
[103].
Distal tubule
We have used the MDCT cell line to determine the effects of
pH changes on cellular Mg2 uptake [146]. The results of these
experiments show that acute alkalosis markedly enhance Mg2
uptake whereas acidosis diminish transport (Fig. 10). Bicarbonate
had no effect on Mg2 entry into MDCT cells. This information
indicates that protons directly affect Mg2 entry through the
Fig. 10. Summary of acid-base, potassium depletion, and phosphate (Pi)
deficiency on the rate of Mg2 entry into MDCT cells. Cell preparation
and fluorescence determinations were performed according to techniques
given in legend to Figure 4. The refill solutions were buffered to 6.0, 7.4,
or 8.0, respectively in these studies. The control cells were cultured in
normal magnesium-deficient media containing 4.8 m potassium and 1.0
m phosphate. Potassium-depleted cells were cultured in 2.5 m potas-
sium and phosphate-deficient cells in 0.3 m phosphate; the other
constituents were normal. Values are means SE for 9 to 10 cells.
*significant, P < 0.05, of Mg2 uptake rate compared to control values.
Data are from Dai et al [33, 146, 1691.
Mg2 transport pathway. A change in extracelluar pH has signif-
icant effects on many kinds of ion channels. Hess and colleagues
proposed that protons titrate an external histidine residue of
L-type Ca2 channels, outside of the permeation pathway, and
reduce channel conductance by an allosteric mechanism [147].
Alternatively, Tsien postulated that protonation of glutamates
within the Ca2 pore itself blocks the permeation pathway [148j.
Our evidence indicates that protonation of the Mg2' pathway
may alter Mg2 influx leading to diminished transport as it does
for Ca2 flux through Ca2 channels.
Metabolic acidosis
As distal luminal fluid pH is normally in the range of 5 to 8, it
is apparent that distal magnesium absorption is physiologically
affected by proton concentration. Metabolic acidosis of any
etiology would be expected to lead to diminished magnesium
reabsorption in the distal tubule. Mather et a! and McNair et al
have reported that 25 and 38%, respectively, of outpatients with
diabetes mellitus have hypomagnesemia [149, 150]. This is due in
part to renal magnesium-wasting stemming from decreased mag-
nesium reabsorption. As we have seen, insulin stimulates magne-
sium reabsorption in the TAL so that insulin deficiency directly
affects magnesium transport in addition to producing ketoacidosis
that inhibits magnesium conservation [1511.
POTASSIUM DEPLETION
Hypokalemia and potassium depletion is associated with dim in-
ished magnesium absorption within the loop and distal tubule that
may lead to increased magnesium excretion [138—1401.
Thick ascending limb
The increase in urinary excretion of divalent cations may be
explained by the well known effects of potassium-depletion on
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NaCI absorption in the thick ascending limb. Chloride conserva-
tion is impaired in potassium-depleted rats which may be related
to altered basolateral Na-K transport resulting in impaired NaC1
transport [152—154]. To date, there is no direct evidence for
changes in magnesium absorption in the thick ascending limb with
potassium-depletion; however, as magnesium and calcium are
absorbed by passive mechanisms, it is probable that impaired
NaCI transport may lead to diminished divalent cation absorption
in this segment [1551.
Distal tubule
Our studies, using isolated MDCT cells suggest that potassium-
depletion may have additional important effects on magnesium
transport within the distal convoluted tubule [331. Cellular K
depletion results in the inhibition of Mg2 uptake into MDCT
cells as determined by microfluorescenee. The mechanism for
diminished Mg2 entry is not known; it is not due to an alteration
in the membrane voltage [33]. Further studies are required to fully
explain the defective distal Mg2 transport associated with cellu-
lar potassium depletion.
BARTTER'S AND GITELMAN'S SYNDROMES
The relationship of potassium and magnesium balance is far
from clear. Many patients with hypokalemia have no problems
with renal magnesium conservation. This is no more evident than
in those patients with Bartter's or Gitelman's diseases [156, 157].
About 30% of patients with Bartter's syndrome develop hypomag-
nesemia whereas those with Gitelman's universally present with
diminished plasma magnesium levels, and yet both diseases are
associated with hypokalemia [158, 1591.
Thick ascending limb
Bartter's syndrome is characterized by hypokalemia, metabolic
alkalosis, hyperprostaglandin production, hyperreninemia, sec-
ondary hyperaldosteronism, and normal blood pressure [156,
159]. The evidence from clinical studies implicates defective salt
transport in the thick ascending limb of the loop [158, 1591. Simon
and colleagues have recently shown with linkage and mutational
analysis that Na-2C1-K cotransport or apical K conductance is
defective [160]. These alterations would be expected to decrease
transepitheial voltage and magnesium reabsorption. It is surpris-
ing that Bartter's syndrome, a defect in loop absorption where the
majority of filtered magnesium is reclaimed, is not more fre-
quently associated with renal magnesium-wasting. About a fifth of
Bartter's patients have abnormal magnesium concentrations
whereas patients with Gitelman's syndrome, due to a distal defect,
uniformly demonstrate hypomagnesemia [159, 161]. Despite the
high incidence of hypercalciuria in Bartter's patients, there is little
effect on renal magnesium handling. Aberrant salt cotransport in
the thick ascending limb would lead to defective magnesium and
calcium absorption and increased delivery to the DCT. It remains
to be determined why magnesium absorption in the DCT pro-
ceeds normally in most of these patients, while calcium is excreted
in the urine. Hypokalemic metabolic alkalosis tends to be less
severe in Bartter's patients so that magnesium reabsorption in the
DCT may not be compromised.
Distal tubule
Gitelman's syndrome refers to a familial disease in which
patients present with hypokalemic alkalosis in conjunction with
hypoealciuria and hypomagnesemia [157]. Some of the features of
Gitelman's syndrome may be observed in patients chronically
receiving thiazide diuretics raising the possibility that loss in
Na-Cl cotransport in the distal tubule could result in this disease.
Again, Simon et al used linkage and mutational analysis to
confirm that Gitelman's syndrome is indeed due to mutations in
the thiazide-sensitive Na-Cl cotransporter [13]. The renal magne-
sium-wasting and hypomagnesemia in Gitelman's patients re-
mains to be explained [14, 162, 163]. However, the results with
MDCT cells suggest that the basis of increased magnesium
excretion may be due to associated hypokalemia. If this is true
then it may be speculated that correction of the potassium deficits
in these patients may also correct renal magnesium-wasting
independent of the genetic aberrations of Na-Cl cotransport.
Colussi et al reported that antialdosterone therapy is effective in
ameliorating hypokalemia and hypomagnesemia in Gitelman's
syndrome [164]. Further studies are warranted to determine the
cellular basis of hypokalemic renal magnesium-wasting.
PHOSPHATE-DEPLETION
One of the hallmarks of hypophosphatemia and cellular phos-
phate-depletion is the striking increase in urinary excretion of
calcium and magnesium [1651. Magnesium excretion may be
sufficiently large to lead to overt hypomagnesemia [166, 167]. The
increase in divalent ion excretion in both human and experimental
animals occurs within hours following initiation of dietary phos-
phate restriction. Three mechanisms have been proposed to
account for the increased renal excretion: (1) mobilization of
calcium and magnesium from bone, (2) suppression of parathy-
roid hormone secretion, and (3) aberrant tubular transport [1651.
Thick ascending limb
It is evident from clearance experiments that the urinary
excretion of divalent cations of phosphate-depleted subjects is
inappropriate for the plasma concentration, supporting the notion
of defective tubular transport [165]. Using micropuncture, we
have demonstrated that defective magnesium absorption occurred
in the loop of Henle and the distal tubule of phosphate-depleted
dogs [168]. The cellular mechanisms involved with diminished
magnesium absorption within the loop of Henle have not been
determined.
Distal tubule
We have shown that cellular phosphate-depletion leads to
diminished Mg2 uptake in MDCT cells [169]. This observation
supports the notion that the DCT may be involved, in part, in
decreased magnesium absorption and increased magnesium ex-
cretion associated with hypophosphatemia. The effects of phos-
phate depletion on Mg2 uptake in MDCT cells are reminiscent
of those observed in the intact kidney. Removal of phosphate
from the media rapidly leads to diminished Mg2 transport, which
is dependent on the degree of phosphate-depletion. Mg2 uptake
is inhibited by 50% when cultured in about 0.3 m phosphate.
These actions are fully reversible with the return of phosphate to
the media. The induction of defective transport that is associated
with phosphate depletion must reside within the cell either to
prevent the normal up-regulation of Mg2 transport with Mg2
deficiency or to inhibit Mg2 uptake through actions on transport
processes. To determine if phosphate-depletion acts through
post-translational mechanisms, MDCT cells were first Mg2
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depleted for 16 hours to maximally up-regulate Mg2 transport.
The cells were then phosphate-depleted for various time periods
and Mg2 uptake was assessed by microfluorescence (Fig. 10).
Phosphate-depletion resulted in diminished Mg2 uptake in
preadapted cells, which suggests it affects transport through
actions on preformed pathways rather than through transcrip-
tional or translational mechanisms. Further studies are necessary
to define these post-translational events. It is evident from these
studies with isolated MDCT cells that magnesium-wasting com-
monly observed with hypophosphatemia and phosphate depletion
could be due, in part, to diminished Mg2 uptake in the distal
convoluted tubule.
Experimental and clinical data suggest an association between
hypomagnesemia and hypokalemia and also hypophosphatemia
[126, 130, 1701. Crook reported a twofold increase in the preva-
lence of hypophosphatemia (plasma phosphate < 0.8 mM) and a
sixfold increase in hypokalemia (plasma potassium < 3.5 mM) in
patients with hypomagnesemia (plasma magnesium < 0.70 mM)
[1701. A trilogy consisting of hypomagnesemia, hypophospha-
temia and hypokalemia was also found in 8% of patients with
hypomagnesemia and 17% of patients with severe hypomag-
nesemia (plasma magnesium < 0.50 mM). The evidence suggests
that hypokalemia and hypophosphatemia may have profound
effects on tubular magnesium transport. Many of the syndromes
associated with potassium depletion and phosphate depletion are
complicated by concurrent alterations in acid-base balance [126,
171]. Our evidence indicates that acid-base changes (H ions)
have different effects on magnesium transport relative to potas-
sium or phosphate depletion so that the three disturbances may
act in an additive manner to compromise renal magnesium
conservation.
SUMMARY
Recent research has provided new concepts in our understand-
ing of renal magnesium handling. Although the majority of the
filtered magnesium is reabsorbed within the ioop of Henle, it is
now recognized that the distal tubule also plays an important role
in magnesium conservation. Magnesium absorption within the
cTAL segment of the loop is passive and dependent on the
transepithelial voltage. Magnesium transport in the DCT is active
and transcellular in nature. Many of the hormonal (PTH, calcito-
ni glucagon, AVP) and nonhormonal (magnesium-restriction,
acid-base changes, potassium-depletion) influences that affect
magnesium transport within the cTAL similarly alter magnesium
absorption within the DCT. However, the cellular mechanisms are
different. Actions within the loop affect either the transepithelial
voltage or the paracellular permeability. Influences acting in the
DCT involve changes in active transcellular transport either Mg2
entry across the apical membrane or Mg2 exit from the basolat-
eral side. These transport processes are fruitful areas for future
research. An additional regulatory control has recently been
recognized that involves an extracellular Ca2 /Mg24 -sensing re-
ceptor. This receptor is present in the basolateral membrane of
the TAL and DCT and modulates magnesium and calcium
conservation with elevation in plasma divalent cation concentra-
tion. Further studies are warranted to determine the physiological
role of the Ca2/Mg2-sensing receptor, but activating and inac-
tivating mutations have been described that result in renal mag-
nesium-wasting and hypermagnesemia, respectively. All of these
receptor-mediated controls change calcium absorption in addition
to magnesium transport. Selective magnesium control is through
intrinsic control of Mg2 entry into distal tubule cells. The cellular
mechanisms that intrinsically regulate magnesium transport have
yet to be described. Familial diseases associated with renal
magnesium-wasting provide a unique opportunity to study these
intrinsic controls. Loop diuretics such as furosemide increase
magnesium excretion by virtue of its effects on the transepithelial
voltage thereby inhibiting passive magnesium absorption. Distally
acting diuretics, like amiloride and chiorothiazide, enhance Mg2
entry into DCT cells. Amiloride may be used as a magnesium-
conserving diuretic whereas chlorothiazide may lead to potassi-
um-depletion that compromises renal magnesium absorption.
Patients with Bartter's and Gitelman's syndromes, diseases of salt
transport in the loop and distal tubule, respectively, are associated
with disturbances in renal magnesium handling. These may pro-
vide useful lessons in understanding segmental control of magne-
sium reabsorption. Metabolic acidosis diminishes magnesium
absorption in MDCT cells by protonation of the Mg2 entry
pathway. Metabolic alkalosis increases magnesium permeability
across the cTAL paracellular pathway and stimulates Mg2 entry
into DCT cells. Again, these changes are likely due to protonation
of charges along the paracellular pathway of the cTAL and the
putative Mg2 channel of the DCT. Cellular potassium-depletion
diminishes the voltage-dependent magnesium absorption in the
TAL and Mg2 entry into MDCT cells. However, the relationship
between potassium and magnesium balance is far from clear. For
instance, magnesium-wasting is more commonly found in patients
with Gitelman's disease than Bartter's but both have hypokalemia.
Further studies are needed to sort out these discrepancies.
Phosphate deficiency also decreases Mg2 uptake in distal cells
but it apparently does so by mechanisms other than those
observed in potassium depletion. Accordingly, potassium deple-
tion, phosphate deficiency, and metabolic acidosis may be addi-
tive. The means by which cellular potassium and phosphate alter
magnesium handling are unclear. Research in the nineties has
increased our understanding of renal magnesium transport and
regulation, but there are many interesting experimental and
clinical areas for future research.
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